Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb, Multicenter, Double-blind, Placebo-controlled Induction Study With an Active Treatment Extension to Assess the Efficacy, Safety, and Pharmacokinetics of RO7837195 in Patients With Moderately to Severely Active Ulcerative Colitis

NCT06979336 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT06979336
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06979336 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb, Multicenter, Double-blind, Placebo-controlled Induction Study With an Active Treatment Extension to Assess the Efficacy, Safety, and Pharmacokinetics of RO7837195 in Patients With Moderately to Severely Active Ulcerative Colitis
Lead sponsor
Genentech, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
September 29, 2025
Completion date
October 31, 2028
Enrollment
224 (estimated)
Sites
108

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis